A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma
Phase of Trial: Phase I/II
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Meningioma
- Focus Adverse reactions; Therapeutic Use
- 01 Jul 2019 Planned number of patients changed from 30 to 38.
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 26 Feb 2019 Planned End Date changed from 30 Sep 2020 to 31 Dec 2021.